Medicine Recommendations

Unlicensed use in Secretory Gastrointestinal Disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea)

Treatment and prophylaxis of schizophrenia

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Rapid tranquilization

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

COPD

Adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis.

Chronic spontaneous urticaria (NICE TA339)

NICE TA339 - Omalizumab for previously treated chronic spontaneous urticaria

Primary and secondary prevention of cardiovascular disease

Parkinson’s disease – adjunctive therapy in adults with end-of-dose motor fluctuations who cannot be stabilised on preparations of levodopa/DOPA decarboxylase inhibitors

Management of patients with skin and soft tissue infections

For Non – Cystic Fibrosis Bronchiectasis

Influenza treatment & prophylaxis (NICE TA158 & 168)

NICE TA158 - Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza

NICE TA168 - Amantadine, oseltamivir and zanamivir for the treatment of influenza

Vulvovaginal or vaginal atrophy in postmenopausal women

Anxiety (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Treatment of epilepsy

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Pain

Restless Legs Syndrome

Chronic pain

For cluster headaches - under review

Palforzia for treating peanut allergy in children and young people (NICE TA769)

NICE TA769 - Palforzia for treating peanut allergy in children and young people